Open AccessConcise Review: Lessons Learned from Islet Transplant Clinical Trials in Developing Stem Cell Therapies for Type 1 Diabetes
Author(s) -
Welsch Carole A.,
Rust William L.,
Csete Marie
Publication year - 2019
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.1002/sctm.18-0156
Subject(s) - islet , medicine , stem cell , transplantation , induced pluripotent stem cell , clinical trial , type 1 diabetes , cell therapy , stem cell therapy , islet cell transplantation , diabetes mellitus , bioinformatics , immunology , intensive care medicine , oncology , embryonic stem cell , biology , endocrinology , microbiology and biotechnology , biochemistry , gene
We examined data and patterns in clinical islet transplant studies registered on ClinicalTrials.gov (CTgov) for treatment of type 1 diabetes (T1D), with a goal of extracting insights to apply in the design of a pluripotent stem cell‐derived islet therapy. Clinical islet transplantation, as a cell therapy (rather than solid organ transplant) is a unique precedent for stem cell‐based islet therapies. Registration activity shows that the field is not growing significantly, and newer registrations suggest that the reasons for stagnation include need for a more optimal site of infusion/transplantation, and especially a need for better immune protective strategies to advance a more effective and durable therapy for T1D. Stem Cells Translational Medicine 2019;8:209&214